News

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types

Dr. Aleix Prat, an internationally recognized leader in drug…

LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors

Dr Mozayeni brings deep experience in biotech corporate strategy…

Philanthropic Partnership Launches New Initiative Tackling Antimicrobial Resistance, the Third-Leading Cause of Death Globally, By Fast-Tracking Discovery of New Treatments

Initiative marks first investment of global health partnership…

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy

225Ac-satoreotide is a first-in-class Actinium-labelled somatostatin…

Liva Healthcare acquires Momenta, and secures funding from new and existing investors to drive growth

Purchase of UK-based Discover Momenta and Momenta Newcastle…

Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion

Financing led by CARMA FUND and RV Invest with participation…

Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology

ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate…

BrightHeart Unveils Breakthrough AI Results at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, Revolutionizing Prenatal Care

Paris, France – January 31, 2025, BrightHeart, a global leader…

Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year

In 2024, on its 100th anniversary, the Novo Nordisk Foundation…

Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform

Additional funding from new investor Korys, joining existing…

Campus Kalundborg takes next step to become a leading hub for education, research and innovation within biomanufacturing and biosolutions

DKK 320 million has been awarded for the development of a new…

Mission Therapeutics announces publication in Nature Reviews Drug Discovery of article highlighting how neurodegenerative diseases can be tackled by enhancing mitophagy

Review article in high impact journal outlines the evidence…

FDA Clears Ariceum Therapeutics’ ²²⁵Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

225Ac-SSO110 (satoreotide) is a first in class Actinium-labelled…

Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology

Bioptimus announces a $76M funding milestone, with the latest…

Ariceum Therapeutics and ITM Enter Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Berlin, Germany / Garching / Munich, January 13, 2025 – Ariceum…

Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A

13 January 2025, Helsinki, Finland: Rappta Therapeutics (“Rappta”),…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

Get in touch

© Optimum Strategic Communications.